Top story
Sales of Novo Nordisk’s obesity drug, Wegovy, rose by 57% last year, although the Danish drugmaker is expecting a slowdown next year.
Novo Nordisk has grown rapidly off the back of rising global demand for GLP-1 obesity treatments, which suppress appetite.
Its net sales grew by 26% in 2024 driven by sales of obesity and diabetes drugs, particularly in the US. Next year, however, it expects sales growth to slow to between 16% and 24%.
Novo Nordisk’s share price is down around 40% since last summer as some investors have begun to question the scale of the obesity drug market.
The repertoire of obesity drugs is rapidly expanding, with Novo Nordisk reporting treatments in late-stage trials are ”among the highest weight reductions yet seen”.
Morning update
UPFs were off the menu in many households last month, as Brits turned to scratch cooking to stay healthy and keep costs down.
Sales of fresh fruit were up 16% in the four weeks to 27 January compared with the same period last year, while fresh veg was up 9%, according to NIQ.
Total till sales were up 5.3% at UK supermarkets, though volumes remain relatively flat, up just 0.9%.
Full story here.
No comments yet